Oasmia Pharmaceutical AB (STO:OASM) announced on Monday that it has appointed Peter Selin as chief business officer, reporting directly to Dr Francois R. Martelet, CEO.
Selin, who has almost 20 years of business development experience, most recently serving as VP Pharma Business Operations at Inceptua Group, a pharmaceuticals company and services provider. His prior roles include appointments at Sobi, where he served as VP Corporate Development and managed partnering and licensing activities and corporate strategy projects, as well as manager, Strategy & Transformation at Ernst & Young.
Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology.
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Enable Biosciences names new chief financial officer
Cadenza Bio names new director
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation